Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present SOLANA BEACH, Calif. , April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
SOLANA BEACH, Calif. , March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that Matthew J.
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
SOLANA BEACH, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has priced an
GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide SOLANA BEACH, Calif. , Oct.
